Omeros receives NIDA grant for NMUR2 drug development program
The grant will fund medicinal chemistry for proprietary compounds that interact with NMUR2 AND Omeros will retain ownership of any compound developed with the assistance of this NIDA
Evogene and ELEO have entered a scientific collaboration aimed at discovering and developing new oral small-molecule inhibitors targeting the Proprotein convertase subtilisin/kexin type 9 (PCSK9) pathway for hyperlipidemia and cardiovascular diseases.